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Drug−drug interactions (DDIs) occur when a patient’s response to the drug is modified by administration or co-exposure to another
drug. The main cytochrome P450 (CYP) enzyme, CYP3A4, is implicated in the metabolism of almost all of the tyrosine kinase inhibitors
(TKIs). Therefore, there is a substantial potential for interaction between TKIs and other drugs that modulate the activity of this
metabolic pathway. Cancer patients are susceptible to DDIs as they receive many medications, either for supportive care or for
treatment of toxicity. Differences in DDI outcomes are generally negligible because of the wide therapeutic window of common
drugs. However for anticancer agents, serious clinical consequences may occur from small changes in drug metabolism and
pharmacokinetics. Therefore, the objective of this review is to highlight the current understanding of DDIs among TKIs, with a focus on
metabolism, as well as to identify challenges in the prediction of DDIs and provide recommendations.
Introduction
Tyrosine kinases are a major family of proteins frequently
dysregulated (either through somatic mutations or over-
expression) in various cancers. Their critical role in the
control of cancer phenotypes, coupled to the presence of
suitable binding domains for small molecules, led to the
development of many tyrosine kinase inhibitors (TKIs) as
anti-cancer agents. As we are able to achieve a better
control of the disease over the longer lifespan of a patient,
these TKIs are now being considered as chronic medica-
tions as they are used over a long period of time. The
increasing number of therapies has improved the progno-
sis for the disease but has augmented the challenge of
evaluating patients for potential drug interactions during
therapy [1].
Drug−drug interactions (DDIs) occur when a patient’s
pharmacological or clinical response to the drug is modi-
fied by administration or co-exposure to another drug.
Pharmacokinetic interactions occur when one drug influ-
ences the pharmacokinetic processes such as absorption,
distribution, metabolism and excretion, of another drug.
Altered metabolism is among the most complex of these
processes by which drug–drug interactions can occur,
and induction or inhibition of hepatic enzymes by drugs
are often implicated. The clinical consequences of
enzyme induction or inhibition depend on the pharmaco-
logical and toxic effect of both the parent drug and its
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metabolite(s). For example, if the parent compound is
more active than its metabolite, inhibition of metabolism
increases the exposure to the drug and also its therapeutic
and/or toxic effects. However, if the parent compound
is a pro-drug, inhibition of metabolism may result in a
decrease in therapeutic efficacy. More recently, another
paradigm of interaction arises when the metabolite is
more toxic, and hence induction of metabolism down this
pathway can exacerbate toxicity.
Central to the metabolism of drugs is the cytochrome
P450 (CYP) family of enzymes. This consists of numerous
enzymes that are responsible for the phase I metabolism
of many drugs, nutrients, endogenous substances, and
environmental toxins. The main CYP enzyme, CYP3A4, is
responsible for the metabolism of more than 50% of all
drugs in the market. It is also implicated in the metabo-
lism of almost all of the TKIs. Therefore, there is a sub-
stantial potential for interaction between TKIs and other
drugs that modulate the activity of this metabolic
pathway.
A recent study revealed that co-prescription of drugs
that induce or inhibit metabolic pathways used by TKIs
was high. Overall co-prescribing rates for DDI drugs that
may decrease TKIs effectiveness ranged from 23–57%,
while co-prescribing rates with drugs that may increase TKI
toxicity ranged from 24–74% [2]. In another study which
studied the pattern of DDIs in cancer patients, the fre-
quency of at least one potential DDI occurring was 63%.
Among them, almost 62% of the identified DDIs were con-
sidered as major, where the effects of the interaction may
result in serious consequences such as hospitalization,
therapeutic failure, permanent injury or even death [3].
Although many studies highlighted the problem of fre-
quent DDIs among TKIs, these studies did not address the
clinical consequences of the potential DDIs, such as
increased toxicity or therapeutic failure. In some cases,
these combinations could have been intentionally pre-
scribed, where physicians may have knowingly prescribed
a potentially interacting combination because they con-
sidered the potential benefits to outweigh the risks or
because the patient had tolerated the combination in the
past [4]. As these TKIs are relatively new to the market, the
scientific evidence that supports their DDI is limited.
Therefore, it is not unexpected to observe that oncology
professionals are unable to identify TKI DDI pairs which
that might have a high probability of causing deleterious
effects in cancer patients [5].
Cancer patients are susceptible to DDIs as they receive
many medications, either for supportive care or for treat-
ment of therapy-induced toxicity [6]. For instance, an
observational study highlighted that patients were receiv-
ing on average 6.8 drugs in addition to sunitinib. Among
them, antihypertensive drugs were most commonly pre-
scribed, followed by analgesics, anti-emetics and thyroid
substitution therapy [7]. In certain cases, a cancer patient’s
pharmacokinetic parameters may be also altered, for
example, oedema affecting volume of distribution or
impaired drug absorption due to malnutrition or
mucositis. These issues may also affect the consequences
of DDIs. Since most cancers typically occur at a later age,
these patients may also be receiving other drugs for the
management of their comorbidities. Differences in DDI
outcomes are generally negligible because of the wide
therapeutic windows of common drugs. However, in
cancer chemotherapy with anti-cancer drugs, serious clini-
cal consequences may occur from small changes in drug
metabolism and pharmacokinetics [8]. Studies conducted
by our group have exhibited the increase in risk of toxicity
as a consequence of DDIs [9]. Sunitinib, a multi-kinase
inhibitor used in the first line treatment of metastatic renal
cell carcinoma, has been associated with dose-limiting
dermatological toxicities such as hand-foot skin reac-
tion (HFSR), rash and dry skin [10]. Sunitinib undergoes
metabolism by CYP3A4 to form an active metabolite,
SU12662 (N-desethyl sunitinib). A recent study has
demonstrated that sunitinib is more dermatotoxic than
SU12662, suggesting that patients who receive concomi-
tant CYP3A4 inhibitors would be at a higher risk of derma-
tological toxicities, due to a lower ability to metabolize
sunitinib [11]. Consequently, this may result in an
increased risk of non-compliance, dose reduction or
therapy discontinuation, thereby leading to suboptimal
therapy.
Due to the substantial potential for interaction
between TKIs and other drugs that modulate the activity
of metabolic pathways, unwanted clinical consequences
may occur from small changes in drug metabolism and
pharmacokinetics in cancer patients. Furthermore, it is
a challenge to determine the clinical effects of the
DDI due to the large inter-patient variability in the
pharmacokinetics of the TKIs. Therefore, the objective of
this review is to highlight the current understanding of
DDIs among TKIs, with a specific focus on DDIs involving
metabolism, and to identify challenges in the prediction of
DDIs and provide some possible recommendations.
Methods
A search was conducted to identify all small mole-
cule TKIs approved by the FDA from January 2000 to Feb-
ruary 2014. A comprehensive literature search of articles
involving TKIs was performed using the PubMed and
Scopus databases. Meetings abstracts presented at the
American Association for Cancer Research (AACR) and
the American Society of Clinical Oncology (ASCO) were
also reviewed. The search was conducted by using the
generic names of all the identified TKIs (afatinib, axitinib,
bosutinib, cabozantinib, crizotinib, dasatinib, erlotinib,
gefitinib, imatinib, lapatinib, nilotinib, pazopanib,
ponatinib, regorafenib, sorafenib, sunitinib, vandetanib),
and terms such as ‘drug interaction’, ‘metabolism’ and
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‘pharmacokinetics’. The search was limited to English lan-
guage articles published between January 1995 and Feb-
ruary 2014.
Results and discussion
Overview of TKIs (Table 1)
There are currently 17 FDA-approved TKIs (as of 31 March
2014) and they are indicated for various malignancies
ranging from solid tumours such as breast and lung
cancers to haematological malignancies like chronic
myeloid leukemia.
Metabolism profile of TKIs (Table 2)
Almost all of the TKIs undergo metabolism by CYP
enzymes. CYP3A4 is the CYP enzyme involved in the
metabolism of the majority of the TKIs. Some of these
TKIs, including imatinib, sunitinib and dasatinib, form
an active metabolite upon metabolism. These TKIs can
also act as an inducer or inhibitor to the CYP enzymes.
All TKIs are primarily excreted in the faeces. However,
the percentage of unchanged drug recovered in the
faeces and urine varies widely between the TKIs. This
could be likely due to the varying degree of absorption of
the drug or due to differences in the extent of drug
metabolism.
Potential effect of enzyme inducers/inhibitors
on the pharmacokinetics of TKIs (Table 3)
As most of these TKIs are substrates of the CYP3A4
enzyme, inducers and inhibitors of this enzyme can
affect the exposure to these TKIs. The most common
inducer and inhibitor used for the study of the potential
pharmacokinetic interaction are rifampicin and keto-
conazole, respectively. As expected, ketoconazole
increases the exposure of TKIs due to the inhibition of
metabolism. However, the extent to which the exposure
is increased varied widely between the TKIs. For instance,
concomitant ketoconazole can result in a slight increase
of imatinib area under the curve (AUC) by 40% [12] but
for bosutinib, the increase in AUC is more than eight
Table 1
Overview of FDA-approved TKIs
Year of FDA
approval Indication(s) Targets
FDA black box
warning Dosing administration Reference
Afatinib (Gilotrif) 2013 Metastatic NSCLC with EGFR
mutations
EGFR, HER2, HER4 40 mg once daily [52]
Axitinib (Inlyta) 2012 Advanced RCC VEGFR-1, VEGFR-2, and VEGFR-3 5 mg twice daily [53]
Bosutinib (Bosulif) 2012 CML Bcr-Abl, Src 500 mg once daily [16]
Cabozantinib
(Cometriq)
2012 Thyroid cancer RET, MET, VEGFR-1, −2 and −3,
KIT, TRKB, FLT-3, AXL, and TIE-2
Haemorrhage 140 mg once daily [54]
Crizotinib (Xalkori) 2011 ALK+ NSCLC ALK, MET, RON 250 mg twice daily [55]
Dasatinib (Sprycel) 2006 CML
Ph+ ALL
Bcr-Abl, Src 100 mg once daily [56]
Erlotinib (Tarceva) 2004 NSCLC
Metastatic pancreatic cancer
EGFR 100–150 mg once daily [57]
Gefitinib (Iressa) 2003 NSCLC EGFR 250 mg once daily [58]
Imatinib (Gleevec) 2001 CML
GIST
Ph+ ALL
Bcr-Abl 300–800 mg once daily* [59]
Lapatinib (Tykerb) 2007 Metastatic breast cancer EGFR, HER2 Hepatotoxicity 1250–1500 mg once daily* [60]
Nilotinib (Tasigna) 2007 CML Bcr-Abl QT prolongation 300 mg twice daily [61]
Pazopanib
(Votrient)
2009 RCC
Soft tissue sarcoma
VEGFR-1, VEGFR-2 and VEGFR-3 Hepatotoxicity 800 mg once daily [62]
Ponatinib (Iclusig) 2012 CML
Ph+ ALL
Bcr-Abl Arterial thrombosis and
hepatotoxicity
45 mg once daily [63]
Regorafenib
(Stivarga)
2012 Metastatic colorectal cancer
GIST
VEGFR2 and TIE2 Hepatotoxicity 160 mg once daily [64]
Sorafenib
(Nexavar)
2005 RCC
Unresectable HCC
KIT, FLT-3, VEGFR-2, VEGFR-3 and
PDGFR-B
400 mg twice daily [65]
Sunitinib (Sutent) 2006 RCC
GIST
pNET
PDGFR (α,β) VEGFR (1, 2, 3), KIT,
FLT3, CSF-1R, RET
Hepatotoxicity 37.5–50 mg once daily* [66]
Vandetanib
(Caprelsa)
2011 Thyroid Cancer EGFR, VEGFR, RET QT prolongation 800 mg once daily [67]
*Dosing administration depends on indication. ALK+, anaplastic lymphoma kinase; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; FDA, Food and Drug
Administration; GIST, gastrointestinal stromal tumour; HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung cancer; Ph+ ALL, Philadelphia chromosome-positive acute
lymphoid leukemia; pNET, progressive, well-differentiated pancreatic neuroendocrine u; RCC, renal cell carcinoma.
Metabolism-related drug−drug interactions with tyrosine kinase inhibitors
Br J Clin Pharmacol / 79:2 / 243
times with concomitant ketoconazole [13]. It is also inter-
esting to note that exposure to TKIs is much increased
by concomitant ketoconazole, as CYP3A4 is the only
enzyme involved in the TKI’s metabolic pathway. This
is also supported by a report by Scripture et al. whereby
drug interactions are likely to be significant when drug
elimination occurs primarily through a single metabolic
pathway [14]. Similarly for rifampicin, the combination of
Table 2
Metabolism profile of FDA-approved TKIs
% of dose recovered
(% recovered unchanged) Metabolism
Induces InhibitsFeces Urine Major CYPs Minor CYPs & others
Afatinib 85 (NR) 4 (NR) Negligible
Axitinib 41 (12) 23 (ND) CYP3A4
CYP3A5
CYP1A2
CYP2C19
UGT1A1
CYP1A2
CYP2C8
Bosutinib 91 (NR) 3 (NR) CYP3A4
Cabozantinib 54 (NR) 27 (NR) CYP3A4 CYP2C9 CYP1A1 CYP2C8
CYP2C9
CYP2C19
CYP3A4
Crizotinib 63 (53) 22 (2) CYP3A4
CYP3A5
CYP3A
CYP2B6
Dasatinib 85 (19) 4 (<1) CYP3A4 FMO-3
UGT
CYP3A4
Erlotinib 83 (1) 8 (<1) CYP3A4 CYP1A2
CYP1A1
CYP1A1
CYP3A4
CYP2C8
Gefitinib 86 (NR) 4 (NR) CYP3A4
CYP2D6
CYP2C19
CYP2D6
Imatinib 68 (20) 13 (5) CYP3A4 CYP1A2
CYP2D6
CYP2C9
CYP2C19
CYP2C8
CYP2C9
CYP3A4/5
CYP2D6
Lapatinib (27) (<2) CYP3A4
CYP3A5
CYP2C19
CYP2C8
CYP3A
CYP2C8
Nilotinib 93 (69) N.R. CYP3A4 CYP2C8 CYP2B6
CYP2C8
CYP2C9
CYP3A4
CYP2C8
CYP2C9
CYP2D6
Pazopanib Majority in faeces 4 CYP3A4 CYP1A2
CYP2C8
CYP1A2
CYP3A4
CYP2B6
CYP2C8
CYP2C9
CYP2C19
CYP2D6
CYP2E1
Ponatinib 87 (NR) 5 (NR) CYP3A4 CYP2C8
CYP2D6
CYP3A5
Regorafenib 71 (47) 19 (2) CYP3A4 UGT1A9 CYP2C8
CYP2C9
CYP2B6
CYP3A4
CYP2C19
Sorafenib 77 (51) 19 (ND) CYP3A4 UGT1A9 CYP2B6
CYP2C8
CYP2C9
CYP2C19
CYP2D6
CYP3A4
Sunitinib 61 (NR) 16 (NR) CYP3A4
Vandetanib 44 (NR) 25 (NR) CYP3A4 FMO-1
FMO-3
All information was obtained from product information labels [68, 69]. ND, not detected; NR, not reported.
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Table 3
Potential effect of enzyme inhibitors/inducers on the pharmacokinetics of TKIs
Changes in PK of TKI Recommendations Reference
Afatinib Unlikely Unlikely [52]
Axitinib Ketoconazole: ↑ 1.5× Cmax, ↑ 2× AUC of axitinib Strong 3A4/5 inhibitors → Avoid; Consider alternative agents;
Consider ↓ dose of axitinib by half
[53, 70, 71]
Rifampicin: ↓ 71% Cmax, ↓ 79% AUC of axitinib Strong 3A4/5 inducers → Avoid; Consider alternative agents
Bosutinib Ketoconazole: ↑ 5.2× Cmax, ↑ 8.6× AUC of bosutinib Strong 3A inhibitors → Avoid [13, 16]
Rifampicin: ↓ 86% Cmax, ↓ 94% AUC of bosutinib Strong 3A inducers → Avoid
Cabozantinib Ketoconazole: ↑ 38% AUC of cabozantinib Strong 3A4 inhibitors → Avoid; Consider ↓ daily dose of
cabozantinib by 40 mg
[54]
Rifampicin : ↓ 77% AUC of cabozantinib Strong 3A4 inducers → Avoid; Consider ↑ daily dose of
cabozantinib by 40 mg
Crizotinib Ketoconazole: ↑ 1.4× Cmax, ↑ 3.2× AUC of crizotinib Strong 3A4 inhibitors → Avoid [55]
Rifampicin: ↓ 69% Cmax, ↓ 82% AUC of crizotinib Strong 3A4 inducers → Avoid
Dasatinib Ketoconazole: ↑ 4× Cmax, ↑ 5× AUC of dasatinib Strong 3A4 inhibitors → Avoid; Consider alternative agents;
Consider ↓ dose of dasatinib to 20 mg daily (for patients taking
100 mg) or 40 mg daily (for patients taking 140 mg)
[56, 72]
Rifampicin : ↓ 81% Cmax, ↓ 82% AUC of dasatinib Strong 3A4 inducers → Consider alternative agents; Consider ↑
dose of dasatinib
Erlotinib Ketoconazole: ↑ 67% AUC of erlotinib
Ciprofloxacin: ↑ 17% Cmax, ↑ 39% AUC of erlotinib
Strong 3A4 inhibitors → Use with caution [57]
Rifampicin: ↓ 58% AUC of erlotinib Strong 3A4 inducers → Consider alternative agents; consider ↑
dose of erlotinib (up to maximum of 450 mg)
Gefitinib Itraconazole: ↑ 51% Cmax, ↑ 78% AUC of gefitinib Strong 3A4 inhibitors → Use with caution [22, 58, 73]
Rifampicin: ↓ 65% Cmax, ↓ 83% AUC of gefitinib
Phenytoin: ↓ 26% Cmax, ↓ 47% AUC of gefitinib
Strong 3A4 inducers → Consider ↑ dose of gefitinib to 500 mg
daily
Imatinib Ketoconazole: ↑ 26% Cmax, ↑ 40% AUC of imatinib
Gemfibrozil*: ↓ 56% Cmax, ↓ 48% AUC of N-desmethylimatinib
Strong 3A4 inhibitors → Use with caution [12, 59, 74–76]
Rifampicin: ↓ 54% Cmax, ↓ 74% AUC of imatinib
EIAEDs: ↓ 68% Ctrough of imatinib
Strong 3A4 inducers → Consider alternative agents
Lapatinib Ketoconazole: ↑ 114% Cmax, ↑ 257% AUC of lapatinib Strong 3A4 inhibitor → Avoid; Consider ↓ dose of lapatinib to
500 mg daily
[60, 77]
Carbamazepine: ↓ 59% Cmax, ↓ 72% AUC of lapatinib Strong 3A4 inducers → Avoid; Consider ↑ dose of lapatinib up to
4500 mg daily (for HER2+ metastatic breast cancer) or 5500 mg
daily (for HR+, HER2+ breast cancer)
Nilotinib Ketoconazole: ↑ 1.8× Cmax, ↑ 3× AUC of nilotinib Strong 3A4 inhibitors → Avoid; Consider ↓ dose of nilotinib to
300 mg daily (in resistant or intolerant Ph+ CML) or 200 mg daily
(newly diagnosed Ph+ CML-CP)
[61, 78]
Rifampicin: ↓ 64% Cmax, ↓ 80% AUC of nilotinib Strong 3A4 inducers → Avoid; Consider alternative agents
Pazopanib Ketoconazole: ↑ 45% Cmax, ↑ 66% AUC of pazopanib Strong 3A4 inhibitors → Avoid; Consider ↓ dose of pazopanib to
400 mg
[62, 79]
Strong 3A4 inducers → Pazopanib should not be used
Ponatinib Ketoconazole: ↑ 47% Cmax, ↑ 78% AUC of ponatinib Strong 3A4 inhibitors → Consider ↓ dose of ponatinib to 30 mg
daily
[63, 80]
Regorafenib Ketoconazole: ↑ AUC of regorafenib Strong 3A inhibitors → Avoid [64]
Rifampicin: ↓ AUC of regorafenib Strong 3A4 inducers → Avoid
Sorafenib Ketoconazole: no change in AUC of sorafenib [65]
Rifampicin: ↓ 37% AUC of sorafenib Strong 3A4 inducers → Consider ↑ dose of sorafenib
Sunitinib Ketoconazole: ↑ 49% Cmax, ↑ 51% AUC of combined sunitinib and
N-desethyl sunitinib
Ritonavir†: ↓ 48% Cmax, ↓ 40% AUC of N-desethyl sunitinib
Strong 3A4 inhibitor → Consider alternative agents; Consider ↓
dose reduction of sunitinib to a minimum of 37.5 mg (GIST &
RCC) or 25 mg (pNET)
[66, 81]
Rifampicin: ↓ 23% Cmax, ↓ 50% AUC of combined sunitinib and
N-desethyl sunitinib
Efavirenz‡: ↑ 410% Cmax, ↑ 390% AUC of N-desethyl sunitinib
Strong 3A4 inducers → Consider alternative agents; Consider ↑
dose of sunitinib to a maximum of 87.5 mg (GIST & RCC) or
62.5 mg (pNET)
Vandetanib Itraconazole: ↑ 9% AUC of vandetanib [15, 67]
Rifampicin: ↓ 40% AUC of vandetanib Strong 3A4 inducers → Avoid
*Gemfibrozil inhibits the CYP2C8-mediated formation of N-desmethylimatinib (equipotent metabolite of parent imatinib). †Ritonavir inhibits the CYP3A4-mediated formation of
N-desethyl sunitinib (equipotent metabolite of parent sunitinib). ‡Efavirenz induces the CYP3A4-mediated formation of N-desethyl sunitinib (equipotent metabolite of parent
sunitinib). AUC, area under the curve; Cmax, maximum concentration; Ctrough, trough concentration; EIAEDs, enzyme-inducing anti-epileptic drugs; GIST, gastrointestinal stromal
tumour; Ph+ CML, Philadelphia chromosome-positive chronic myeloid leukemia; Ph+ CML-CP, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase; PK,
pharmacokinetics; pNET, progressive, well-differentiated pancreatic neuroendocrine tumours; RCC, renal cell carcinoma; TKI, tyrosine kinase inhibitor.
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drugs resulted in a decrease in exposure to the TKIs.
However, the extent to which the exposure is decreased
is not as large as that observed with ketoconazole. The
decrease in TKI AUC ranged from 40% for vandetanib [15]
to 94% for bosutinib [16]. Among all the TKIs, sorafenib
seems to be an exception, where studies have con-
sistently demonstrated that clinically important interac-
tions between sorafenib and drugs metabolized primarily
by CYPs 3A4, 2C19, or 2D6 are not expected [17, 18].
Although co-administration of sorafenib with capeci-
tabine has been shown to result in a mild increase in
capecitabine exposure, these findings were not statisti-
cally significant and the mechanism of interaction is
unclear [19]. As strong CYP3A4 inducers and inhibitors
generally cause a change in exposure, the concomitant
use of such agents with TKIs is not recommended and
should be avoided if possible. If such combinations must
be used, manufacturers generally recommend that dose
increase or decrease may be considered and that patients
should be monitored closely following any changes in
dosages.
Effect of TKIs as enzyme inducers/inhibitors on
the pharmacokinetics of other drugs
While the effect of enzyme inhibitors or inducers (such as
ketoconazole and rifampicin) on the pharmacokinetics of
TKI has been extensively studied, the reciprocal effect of a
TKI acting as an enzyme inducer or inhibitor has been com-
paratively less investigated. The ability for TKIs to increase
or decrease plasma concentrations of non-anticancer
drugs is mainly unclear, especially within in vivo condi-
tions. Concomitant imatinib and simvastatin has resulted
in a two-fold increase in simvastatin’s maximum plasma
concentraction (Cmax) and a three-fold increase in
simvastatin AUC. This is likely due to inhibition by imatinib
of the CYP3A4 enzyme, which is responsible for the
metabolism of simvastatin to other metabolites. This also
suggests that in the presence of imatinib, plasma concen-
trations of standard doses of drugs which are degraded by
the CYP3A4 enzyme may also be increased. As such,
caution is required when imatinib is administered with
other CYP3A4 substrates with a narrow therapeutic
window [20]. Imatinib has also been shown to increase the
exposure to metoprolol (23% increase in metoprolol AUC)
when both agents are used together, due to the inhibition
of the CYP2D6 enzyme by imatinib [21]. Although the
combination of gefitinib and metoprolol also resulted in
an increased exposure to metoprolol (35% increase in
metoprolol AUC), this change was not statistically signifi-
cant. Despite this, gefitinib has a potential to increase
plasma concentrations of CYP2D6 substrates and caution
should be exercised when using CYP2D6 substrates
that have a narrow therapeutic window [22]. Concomitant
use of two TKIs has also been investigated in certain cases.
Clearance of erlotinib was markedly enhanced by
sorafenib when the two agents were given concurrently,
although the potential mechanism for this seeming
interaction is not obvious [23]. In another example,
co-administration of lapatinib and pazopanib led to an
increase in pazopanib exposure, and it has been sug-
gested that this might be the result of inhibition of CYP3A4
and/or cellular transporters such as ABCB1 and ABCG2 by
lapatinib [24]. The effect of lapatinib on the clearance of
vinorelbine has also been studied, where lapatinib
resulted in a lower clearance of vinorelbine due to the
inhibition of CYP3A4 [25].
Applicability of in vitro and in vivo data
within clinical practice
The majority of the available pharmacokinetic information
results from in vitro data, preclinical animal studies or from
small phase I studies which evaluated healthy volunteers
who were administered a single dose of the drugs. Emerg-
ing methods include creating a simulator where in vivo
clearances can be predicted from their in vitro data. For
instance, the impact of co-administration of ketoconazole
was simulated and the predicted two-fold increase in
erlotinib exposure was found to be consistent with the
results of a clinical study [26]. However, in most cases, the
prediction may not be entirely accurate, especially when
most of these studies evaluate DDIs in the form of two
interacting drugs, and these results may not be realistic
where multiple drugs are used concurrently. In addition,
several reasons have been proposed to highlight the
inability of clinical interactions to be predicted accurately.
Firstly, it is not always possible to determine the therapeu-
tic concentration of a new drug and its metabolites in
specific tissues. To complicate the issue further, the multi-
plicity of enzymes and transporters involved in the dispo-
sition of the said drugs and the intricacy of the pathways
and interactions, in addition to overlapping substrate
specificities of these proteins, results in complex and
sometimes perplexing pharmacokinetic interactions with
multidrug regimens. Large differences in genotype and
expression level of each of these contributors can lead to a
very complex influence on actual drug disposition. There
can also be compensatory responses when one enzyme or
transporter is inhibited, ‘cushioning’ any resulting change
in metabolism. Each drug has a different level of depend-
ence on intrinsic clearance for its overall clearance. Drugs
with a high extraction ratio may be less sensitive to
enzyme inhibition and induction, as their clearance is
limited by blood flow rather than intrinsic activity. This
makes it very challenging to test all of them in an in vitro
system. Furthermore, the clinical significance of an inter-
action is unknown even if the in vitro or in vivo effect was
established. Moreover, underlying disease states may
influence the occurrence of an interaction that is unac-
counted for by in vitro studies or by studies involving
healthy volunteers alone [27, 28]. Endogenous CYP
isoforms expressed in tumour cells also contributes to
the metabolism of active drug, thereby playing a role in
Y. L. Teo et al.
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altering the half-life and kinetics of the administered TKI
[29]. In summary, it is complex and challenging to extrapo-
late these preliminary results to routine clinical practice,
where TKIs are used to treat patients with cancer, many of
whom are receiving multiple drugs and many of whom
have impaired renal or hepatic function [30].
Formation of reactive
intermediates/metabolites and implications
for toxicity
Several TKIs such as dasatinib, erlotinib, gefitinib, imatinib,
lapatinib, nilotinib, pazopanib, sorafenib and sunitinib
undergo bioactivation to form reactive intermediates,
which has implications in the generation of idiosyncratic
adverse drug reactions (ADR) [31]. One TKI whose metabo-
lism and implications for toxicity has been extensively
studied is lapatinib. Lapatinib has been shown to be
extensively metabolized, as exemplified by diverse bio-
transformations to form metabolites. A number of the
metabolites could potentially form reactive electrophilic
intermediates that could contribute to hepatotoxicity [32].
It is also worthy of note that the daily dose of these TKIs is
high. For example the daily dose of lapatinib is more than
1000 mg. A high daily dose of more than 50 mg has been
demonstrated to be a risk factor for ADRs [33]; thereby
setting 13 out of the 17 approved TKIs at risk. Due to the
high dose, there would be high amounts of these reactive
intermediates or metabolites generated, thus increasing
the risk for toxicity [34]. A recent study also further dem-
onstrates that a dose more than 100 mg daily and being a
substrate of CYP450 enzymes are two important predic-
tors of drug-induced liver injury [35].
Actual drug−drug interaction cases involving
TKIs as documented in the literature (Table 4)
There have been several reports demonstrating actual DDI
cases in clinical practice. The events reported were poten-
tially fatal ones such as hepatotoxicity and anticoagulation
abnormalities. The concomitant use of imatinib and
voriconazole resulted in markedly elevated concentrations
of imatinib (between 3500–4700 ng ml−1), than compared
with when imatinib was used alone (2000 ng ml−1). The
raised plasma concentrations resulted in severe pustular
eruption in the patient, and this was deemed due to the
inhibition of imatinib metabolism by voriconazole [36].
Transaminase elevations have also been observed in drug
pairs involving pazopanib and simvastatin. As both drugs
are substrates of the same enzymes and transporters,
it is plausible that the concomitant administration of
pazopanib and statins may alter systemic and/or hepatic
exposures, leading to increased toxicities such as liver
injury [37]. In a study implicating interaction between
lapatinib and dexamethasone, both in vitro and clinical
results points to the increased risk of hepatotoxicity when
the combination of drugs was used together. It has been
proposed that the concomitant use may cause an increase
in the metabolism of lapatinib by dexamethasone, thereby
increasing the formation of lapatinib-derived reactive
metabolites, and leading to toxicity [9]. However, this list
of DDI cases is not exhaustive as there remains a possibility
that many DDI cases remains unreported in the literature.
Even if the drug pair is not listed in this table, it does not
indicate that it is entirely safe for use. Healthcare profes-
sionals should still be aware of the potential interactions
that may occur, and be vigilant in monitoring those
patients who are receiving any potentially-interacting
drug pairs.
Challenges
The large amount of published research into drug interac-
tions might have overwhelmed most healthcare practi-
tioners. As a clinician cannot know all potential clinically
significant drug interactions, this emphasizes the need
for practical identification and management systems [6].
The inefficiency of updating and maintaining drug labels
poses a serious threat to patients. For example, despite
the recent evidence supporting a larger contribution of
CYP2C8 and a less significant role for CYP3A4 in the
metabolism of imatinib, drug labels continue to warn
against potential interactions with CYP3A4 inhibitors but
fail to mention any risk with a CYP2C8 inhibitor [38]. Few
databases and software programs are capable of checking
for all potential interactions among multiple medications.
More importantly, the absence of reported interactions
does not guarantee a lack of interaction [39].
Recommendations
The majority of the phase I trials have evaluated two drug
combinations of therapeutic interest, rather than combi-
nations hypothesized to have a DDI. When DDI studies
were performed with a clear rationale, the probability of
identifying a DDI increased from 8% to 32%. This demon-
strates the importance of understanding the mechanism
behind a DDI and the value to which this translates
clinically and suggests that DDI studies should only be
performed when there is a pre-specified plausible
hypothesis [40].
Most pharmacokinetic studies would report changes in
TKI exposure as a result of the enzyme inhibitor or inducer.
However it would be useful if the investigators also pro-
vided information regarding its potential effect on toxicity
or efficacy [41].
It is imperative that comprehensive and accurate infor-
mation be collected on the use of medications by patients,
to increase awareness and familiarity with potential DDIs
to ensure patient safety and to aid the development of
optimal therapy [42, 43]. To reduce the potential for unex-
pected drug interactions during therapy, the patient’s
medical history should be taken thoroughly and interac-
tively, and updated periodically [1]. Patients who have risk
factors for potential DDIs should also be monitored more
closely. Risk factors for potential DDI include liver function
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Table 4
Actual drug−drug interaction cases involving TKIs as documented in the literature
TKI Interacting drug Event Remarks Recommendations Reference
Gefitinib Anastrozole Liver toxicity Routinely monitor liver transaminases
in all patients treated with
gefitinib
[82]
Warfarin Coagulation abnormalities
(Prothrombin time [PT] and
international normalized
ratio [INR] abnormalities)
Gefitinib could inhibit the metabolism
of warfarin, which is a substrate of
CYP1A2, CYP2C9, and CYP3A4.
The degree of the inhibitory effect
of gefitinib on CYP enzymes varies
from patient to patient. This may in
part explain the variability of the
PT-INR values observed on the
coadministration of gefitinib and
warfarin
Close monitoring of PT-INR is
recommended for patients receiving
gefitinib and warfarin, especially
during the first 2 weeks after the
beginning of warfarin therapy.
Appropriate adjustment of the
warfarin dose should be done if an
altered response to warfarin is
observed.
[83]
Imatinib Voriconazole Severe pustular eruption Plasma concentrations of imatinib
markedly elevated during
simultaneous administration with
voriconazole, possibly due to
inhibition of imatinib metabolism by
voriconazole
Use of imatinib in association with
CYP3A4 inhibitors has to be
considered with caution. When
such an association is considered,
the monitoring of imatinib plasma
levels in patients may be of help for
identifying individuals with high
imatinib concentrations who are at
risk of developing toxicity, including
skin lesions.
[36]
Amlodipine Peripheral neuropathy Amlodipine inhibits CYP3A4, which
could increase imatinib
concentrations
Therapeutic monitoring of plasma
imatinib levels may be useful to
investigate unexpected imatinib
toxicity.
[84]
Phenytoin AUC of imatinib was decreased by
about 80%. After phenytoin was
discontinued and the imatinib dose
was increased to 500 mg daily, a
complete haematological response
was observed.
– [85]
Levothyroxine Hypothyroidism Mechanism unclear Evaluate thyroid function in
hypothyroid patients on tyrosine
kinase inhibitors
[86]
Lapatinib Dexamethasone Hepatotoxicity Concomitant use may cause an
increase in metabolizing capacity by
dexamethasone, which in turn
increases the formation of
lapatinib-derived RM thereby
elevating the risk of toxicity
Clinicians should be aware of this risk
when considering the use of this
combination and follow through
with close monitoring where
necessary.
[9]
Pazopanib Simvastatin Transaminase elevations As pazopanib and statins are
substrates for the same key
metabolizing enzymes e.g. CYP3A4
and drug transporters, it is plausible
that concomitant administration of
pazopanib and statins may alter
their systemic and/or hepatic
exposures, leading to increased
toxicities such as liver injury
In addition to implementing the
recommended dose modification
guidelines for pazopanib,
discontinuation of simvastatin
should be considered to manage
the risk of liver injury in cancer
patients receiving both medications
[37]
Sorafenib Prednisolone Serum concentration of sorafenib was
gradually increased following
tapering of prednisolone, possibly
due to prednisolone inducing
sorafenib metabolism
Therapeutic drug monitoring could be
useful during sorafenib therapy in
combination with prednisolone and
for determining the optimal dosage
of sorafenib.
[87]
Sunitinib Levothyroxine Hypothyroidism Mechanism unclear Evaluate thyroid function in
hypothyroid patients on tyrosine
kinase inhibitors
[86]
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status, age, tumour type [44], number and type of medica-
tions received [45] and using drugs that are metabolized
exclusively by only one CYP isoform [46].
When drugs with potential DDIs are considered for use
with TKIs, clinicians should also consider alternative agents
that have no or less interaction potential. However, it is
also important to note that in some cases, switching to an
alternative agent does not have any significant difference
on the pharmacokinetic profile. For instance, despite
azithromycin having a low potential for interaction, there
was no significant effect of oral clarithromycin or
azithromycin on the pharmacokinetic profile of sunitinib
after single administration [47]. Because we do not know
the clinical effects of these potential interactions when
drugs with potential DDIs need to be used with TKIs (e.g. in
cases where there is a compelling indication for the poten-
tial interacting drug to be used), more intense patient
monitoring for interactions is needed. Scripture et al. have
provided a valuable summary of the conditions where
drug interactions are likely to be clinically significant, such
as when drug elimination occurs primarily through a single
metabolic pathway or when one or both of the interacting
drugs has a steep dose−response curve or a narrow thera-
peutic range etc [14].
Utilization of therapeutic drug monitoring
(TDM) in DDIs
The prerequisites of being a candidate for therapeutic
drug monitoring (TDM) in clinical practice include long
term therapy, significant inter-individual but limited intra-
individual PK variability, narrow therapeutic index, a well-
defined exposure−response (efficacy/toxicity) relationship
and availability of appropriate bio-analytical methods for
quantification [48–51]. As most of the TKIs fulfil the tradi-
tional criteria for a TDM programme, the role of TDM in
TKI therapy is increasingly being studied. Furthermore, as
TKIs have the potential to be involved in multiple interac-
tions (e.g. drug−drug, drug−food and drug−herb) involv-
ing pharmacokinetic or pharmacodynamic pathways,
TDM could complement clinical evaluation by providing
additional information on efficacy, adherence and toxicity
[51].
The application of TDM may be useful in DDIs for
several reasons: for monitoring of patient when high risk
drug pairs cannot be avoided, for diagnosis of DDIs and for
dose adjustments [49]. In such cases, the changes in drug
concentrations, together with the patient’s response and
toxicity, could be used together to make an informed deci-
sion, on whether the drug pair can be continued safely or
whether dose adjustments should be performed. For
example, in a recent study conducted by our group, we
have demonstrated that sunitinib is more dermatotoxic
than its active metabolite, SU12662 [11]. If sunitinib is used
concomitantly with a CYP3A4 inducer, the total effective
plasma concentration (sunitinib and SU12662) may still be
above the therapeutic target. However, patients may
experience less toxicity due to the lesser accumulation of
the parent drug.
Although TDM of TKIs is still in its infancy, there is
increasing evidence that dose adjustments based on
pharmacokinetic targets would help to increase efficacy
and reduce toxicity of TKIs, and might be beneficial for
patients treated with most of the TKIs [50]. Currently,
target plasma concentrations of TKIs and their respective
dose-adaptation strategy are only available for several
of the FDA-approved TKIs. Recommended therapeutic
targets for efficacy are available for crizotinib, erlotinib,
gefitinib, imatinib, nilotinib, pazopanib and sunitinib, and
targets for safety are available for dasatinib and sunitinib
[50]. Thus, application of TDM may be limited to those TKIs
which have a recommended target and may be challeng-
ing in those TKIs which have a lack of information.
Although there are recommended therapeutic targets
available for some of the TKIs, no prospective studies
have been conducted to validate these targets, and thus
applications of TDM may best be reserved for individual
situations relating to a lack of therapeutic response, severe
or unexpected toxicities, drug−drug interactions or
treatment adherence [51]. In summary, future research
should focus on the role and benefits of TDM in
TKI therapy, especially those with a well-established
dose−response relationship and well-established phar-
macokinetic targets. Prospective, randomized studies
should be performed to confirm the benefits of implemen-
tation of TDM, such as reductions in toxicity and/or
improvement in outcomes.
Summary and recommendations
As we are able to achieve a better control of the disease
over the longer lifespan of a patient, TKIs are now being
considered as chronic medications taken in an outpatient
setting. Due to the large inter-patient variability in
pharmacokinetics of these TKIs, any potential DDI could
have serious consequences in a patient’s therapy. Thus far,
there have been numerous phase I and in vitro studies
conducted to evaluate DDIs. This information has been
incorporated into drug labels or drug information data-
bases, to warn prescribers of the risk of such DDIs.
However, as previously mentioned, it is somewhat chal-
lenging to extrapolate results from phase I and in vitro
studies to routine clinical practice. During the drug devel-
opment phase, potentially clinically relevant drug interac-
tions are not usually detected. Only after receiving
regulatory approval and after widespread usage, would a
new DDI typically surface. Therefore, healthcare profes-
sionals, especially physicians and pharmacists, play a vital
role in identifying these new interactions. Perhaps sched-
uled drug utilization reviews could be conducted routinely
to identify any common DDI pairs. Prospective data could
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then be collected regarding these DDI pairs, to identify any
increase in toxicity or lack of efficacy events. Where possi-
ble, investigators could also subsequently recreate the
interaction in an in vitro system to determine the mecha-
nisms which may be involved. However, such research
takes time and in the meantime, suspected DDI pairs
would have to be used cautiously in patients. Neverthe-
less, using both clinical and in vitro data to validate claims
of potential DDIs would ensure accuracy of data as well as
clinical relevance. The utilization of TDM in DDIs may be
useful when high risk drug pairs cannot be avoided, espe-
cially during initiation of therapy or when there is lack of
response or occurrence of severe toxicities. Instead of
withholding a beneficial drug therapy from a patient, the
high risk drug pair may be continued safely with regular
monitoring if the patient is not experiencing excessive tox-
icity, even when the drug concentrations are increased. In
these situations, using additional information on drug
concentrations together with patient’s response and tox-
icity data, a more informed decision can be made.
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